Corbus Pharmaceuticals Files 8-K
Ticker: CRBP · Form: 8-K · Filed: Sep 16, 2025 · CIK: 1595097
Sentiment: neutral
Topics: 8-K, regulatory-disclosure, financials
TL;DR
Corbus Pharma dropped an 8-K on 9/16 - check for Reg FD, other events, and financials.
AI Summary
Corbus Pharmaceuticals Holdings, Inc. filed an 8-K on September 16, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company, incorporated in Delaware, is located at 500 River Ridge Drive, Norwood, Massachusetts.
Why It Matters
This 8-K filing provides updates on Corbus Pharmaceuticals' corporate activities, including regulatory disclosures and financial information, which are important for investors to monitor the company's status.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting standard corporate events and disclosures, not indicating any immediate or significant risks.
Key Numbers
- 001-37348 — SEC File Number (Identifies the company's filing with the SEC)
- 46-4348039 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Corbus Pharmaceuticals Holdings, Inc. (company) — Registrant
- September 16, 2025 (date) — Date of earliest event reported
- 500 River Ridge Drive Norwood, Massachusetts 02062 (location) — Principal Executive Offices
- Delaware (jurisdiction) — State of Incorporation
FAQ
What specific events are being disclosed under Regulation FD?
The filing indicates a Regulation FD Disclosure item, but the specific details of the disclosure are not provided in the provided text.
What are the 'Other Events' reported in this 8-K?
The filing lists 'Other Events' as an item, but the specific nature of these events is not detailed in the provided text.
What financial statements and exhibits are included with this filing?
The filing states 'Financial Statements and Exhibits' are included, but the content of these is not specified in the provided text.
When was Corbus Pharmaceuticals Holdings, Inc. incorporated?
Corbus Pharmaceuticals Holdings, Inc. was incorporated in Delaware.
What is the primary business of Corbus Pharmaceuticals Holdings, Inc. according to its SIC code?
According to its Standard Industrial Classification code [2834], Corbus Pharmaceuticals Holdings, Inc. is in the business of Pharmaceutical Preparations.
Filing Stats: 604 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-09-16 08:45:28
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CRBP The Nasdaq Capital M
Filing Documents
- crbp-20250916.htm (8-K) — 49KB
- crbp-ex99_1.htm (EX-99.1) — 19KB
- 0001193125-25-204389.txt ( ) — 183KB
- crbp-20250916.xsd (EX-101.SCH) — 31KB
- crbp-20250916_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 16, 2025, Corbus Pharmaceuticals Holdings, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has granted Fast Track designation to CRB-701 for the treatment of recurrent or metastatic head and neck squamous cell carcinoma previously treated with platinum-based chemotherapy and an anti-PD(L)-1 therapy. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by a specific reference in such filing.
01 Other Events
Item 8.01 Other Events. On September 16, 2025, the Company announced that the FDA granted Fast Track Designation to CRB-701 for the treatment of recurrent or metastatic head and neck squamous cell carcinoma previously treated with platinum-based chemotherapy and an anti-PD(L)-1 therapy.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) The following exhibit is furnished with this report: Exhibit No. Description 99.1 Press Release issued by Corbus Pharmaceuticals Holdings, Inc. dated September 16, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Corbus Pharmaceuticals Holdings, Inc. Date: September 16, 2025 By: /s/ Yuval Cohen Name: Yuval Cohen Title: Chief Executive Officer